Cancer Epigenetics Program (03)

癌症表观遗传学计划 (03)

基本信息

批准号：
9754616
负责人：
Johnathan R. Whetstine
金额：
$ 4.16万
依托单位：
RESEARCH INST OF FOX CHASE CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9754616
关键词：
Abbreviations Address Antineoplastic Agents Applied Research Basic Science Bioinformatics Biological Biological Markers Biology Biometry Blood Cells Cancer Biology Cancer Center Support Grant Cancer Control Cancer Etiology Cancer Intervention Cell Culture Techniques Cell Separation Clinic Clinical Clinical Research Clinical Trials Collaborations Colon Carcinoma Complex Comprehensive Cancer Center DNA DNA Methylation Detection Development Diagnosis Direct Costs Disease Drug Targeting EZH2 gene Enhancers Environment Epigenetic Process Faculty Fostering Fox Chase Cancer Center Foxes Funding Gene Expression Genetic Transcription Genomics Goals Health system Hematologic Neoplasms Histopathology Facility Interleukin-6 Intervention Investigation Knowledge Laboratory Animals Malignant Neoplasms Malignant neoplasm of urinary bladder Mediating Mission Molecular Molecular Target Morbidity - disease rate Mutation Normal Cell Outcome Participant Patients Pattern Peer Review Pharmaceutical Preparations Population Study Preventive Intervention Proteins Publications Reader Regulation Reporting Research Research Personnel Resource Sharing Risk Assessment Role Scientist Solid Neoplasm Structure System Testing Therapeutic Therapeutic Intervention Tissues Training Transgenic Mouse Facility Translating Translational Research Universities University Hospitals Untranslated RNA Validation Work animal facility cancer biomarkers cancer cell cancer prevention cancer risk cancer therapy career clinically relevant demethylation design early detection biomarkers epigenetic regulation epigenetic therapy epigenome epigenomics high throughput screening histone modification imaging facilities improved improved outcome interest leukemia malignant breast neoplasm medical schools member molecular modeling mortality multidisciplinary next generation novel novel strategies outcome forecast outcome prediction preclinical study programs recruit repository response specific biomarkers standard of care targeted treatment translational clinical trial

项目摘要

PROJECT SUMMARY/ABSTRACT – CANCER EPIGENETICS PROGRAM The Cancer Epigenetics (CE) Program, led by Issa and Studitsky is a new Program at Fox Chase Cancer Center (FCCC). The CE Program is designed to integrate basic and applied research in the field of epigenetics. It is comprised of 19 Primary Members. Program funding is $5M (project direct costs) annually, including $2.4M in peer-reviewed funding of which $1M is from the NCI. CE members have been highly productive since Program initiation in 2012, generating 232 publications, with 9% representing intra- programmatic and 27% representing inter-programmatic collaborations. The CE Program takes advantage of the breadth and depth of faculty expertise in cancer epigenetics arising from the 2012 affiliation between FCCC and Temple University, to advance the overall goal of improving cancer outcomes through new approaches in detection, prognosis and therapy. The CE Program has four overarching themes: 1) Epigenomics: To decipher normal and cancer epigenomes, with the translational goal of discovering biomarkers of cancer risk, prognosis and response to therapy; 2) Readers, Writers and Erasers: To study the proteins that establish, read, modulate and perpetuate epigenetic marks, with the translational goal of discovering potential targets of therapy; 3) Development and Disease: To study epigenetics in normal and abnormal development and relate this information to what is known about cancer epigenetics and biology. The translational goal of this theme is in understanding cancer etiology, and discovering ways to reprogram the epigenome for therapeutic purposes; 4) Epigenetic Therapy: To develop epigenetically-targeted therapeutic approaches and test them in pre-clinical and clinical studies. These themes are developed by investigators working in multidisciplinary teams to identify and address the complex factors that contribute to cancer risk, cancer development and cancer treatment. This new Program was made possible by the recruitment of multiple faculty members at all career stages (junior and senior) and with diverse interests (basic to clinical), and has resulted in a strongly integrated program with both R01 funded basic research and rapidly accruing investigator-initiated clinical trials. These collaborative efforts have created a productive research environment that fosters the identification of new biomarkers of cancer risk, novel molecular targets for preventive intervention, and the successful development and implementation of novel approaches to cancer therapy. CE Program members have successfully accrued 394 research participants into interventional and non-interventional studies during the last funding cycle, and have benefited from the use of 11 of the 12 CCSG-supported Shared Resources at FCCC.

项目摘要/摘要 - 癌症表观遗传学计划由Issa和Studiosky领导的癌症表观遗传学（CE）计划是Fox Chase Cancer的新计划中心（FCCC）。 CE计划旨在将基本和应用研究集成到现场表观遗传学。其中包括19名主要成员。计划资金每年为500万美元（项目直接费用），包括240万美元的同行评审资金，其中100万美元来自NCI。 CE成员很高自2012年计划启动以来的生产力，产生了232份出版物，其中9％代表内部程序化和27％代表程序间合作。 CE计划利用癌症表观遗传学专业知识的广度和深度从2012年FCCC和Temple University之间的分支机构，可以促进改进的总体目标通过检测，预后和治疗的新方法获得癌症结果。 CE计划具有四个总体主题：1）表观基因组学：破译正常和癌症基因组学，，以发现癌症风险，预后和对治疗反应的生物标志物的翻译目标； 2）读者，作家和橡皮擦：研究建立，阅读，调节和永久遗传的蛋白质标记，其转化目标是发现潜在的治疗靶标； 3）发展和疾病：研究正常和异常发育中的表观遗传学，并将此信息与已知癌症表观遗传学和生物学。这个主题的翻译目标是了解癌症的病因，以及发现用于治疗目的的表观基因组的方法； 4）表观遗传疗法：发展表观遗传靶向的治疗方法并在临床前和临床研究中对其进行测试。这些主题由在多学科团队中工作的调查人员开发，以识别和解决复杂因素这有助于癌症风险，癌症发育和癌症治疗。这个新程序被制定了在所有职业阶段（大三和高级）和潜水员的所有职业阶段招募多个教职员工可能可能兴趣（基本上是临床），并与R01资助的基本有关研究并迅速累积研究者发起的临床试验。这些协作努力创造了一个促进癌症风险新生物标志物的生产研究环境，新型预防干预的分子靶标，以及新颖的成功发展和实施癌症治疗方法。 CE计划成员已成功地将394名研究参与者纳入在上一个融资周期中的介入和非介入研究，并从使用中受益在FCCC的12个CCSG支持的共享资源中，有11个。